http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박용순,William S. Harris 한국식품영양과학회 2009 Journal of medicinal food Vol.12 No.4
The purpose of this study was to determine dose effects of n-3 polyunsaturated fatty acids (PUFAs) on mean platelet volume (MPV) and platelet count (PLT-CT) in mildly hypertriglyceridemic subjects. Subjects with a serum triglyceride level between 100 and 300mg/dL were placed on a corn oil placebo for 4 weeks and then randomly assigned to groups taking seven capsules per day of placebo (n=47) or one of the following doses of n-3 PUFAs for 20 weeks: 0.5g (n=50), 1g (n=23), or 2g (n=12). At the end of both the placebo period and the treatment period, MPV and PLT-CT were measured without stimulation (baseline 1 following placebo period, baseline 2 following n-3 supplement period) and after ex vivo stimulation with collagen (10μg/mL), cold (4°C), and heat (37°C). Collagen and cold significantly increased MPV, whereas heat lowered MPV regardless of treatment. All stimuli decreased PLT-CT. Only the 2g/day dose of n-3 PUFAs increased MPV at baseline 2 (7.2±0.5 vs. 7.5±0.5fL) and after the cold stimulus (7.5±0.5 vs. 7.8±0.5 fL). There was no dose-dependent effect of n-3 PUFAs on platelet activation; rather, 2g of n-3 PUFAs increased MPV slightly in mildly hypertriglyceridemic subjects.
Park, Yong-Soon,Harris, William S. The Korean Society of Food Science and Nutrition 2009 Journal of medicinal food Vol.12 No.4
The n-3 polyunsaturated fatty acids (PUFAs) are known to reduce risk for coronary heart disease partly by altering blood lipids. The purpose of this study was to determine the effect of low doses of n-3 PUFAs on the lipid profile and their tolerability in mildly hypertriglyceridemic subjects. Subjects with a serum triacylglycerol (TG) level between 100 and 300 mg/dL were placed on a corn oil placebo (seven capsules per day; single-blind) for 4 weeks and then randomized to continue seven capsules per day of placebo (n=49) or one of the following doses of n-3 PUFAs for 20 weeks: 0.5 g (n=51), 1g (n=23), or 2 g (n=12). During the treatment period, 48.50% of the 1-g and 2-g dose groups reported noticing burping (P < .05), and only about half as many in the 0.5-g group noticed burping. Interestingly, 2% of those assigned to the placebo did report a fishy burping during the study, but this dropped back to nearly 0% by week 20. There was no significant effect for any dosage group on fasting and postprandial serum TG, chylomicron TG, very-low-density lipoprotein-cholesterol, or high-density lipoprotein-cholesterol concentration. However, 1-g and 2-g n-3 PUFA treatments significantly increased total cholesterol and low-density lipoprotein-cholesterol concentration. In addition, all doses of n-3 PUFA treatments significantly increased plasma phospholipid n-3 PUFAs. We conclude that doses of n-3 PUFAs of 0.5.2 g/day in healthy volunteers with above average TG levels did not have beneficial effects on their lipid profiles.